FIELD: medicine.
SUBSTANCE: invention claims combined application of CB1 cannabinoid receptor antagonistic rimonabant with AT1 angiotensin II receptor antagonist, individually or in combination with diuretic or calcium anagonist, for obtainment of medicine for prevention and treatment of diseases related to dyslipidemia and/or obesity, selected out of metabolic syndrome and steatorrheic hepatitis. Additionally invention claims respective pharmaceutical combination.
EFFECT: synergy of the claimed combination in cholesterol level reduction.
5 cl, 6 tbl, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DIBENZOSUBERONE DERIVATIVES | 2005 |
|
RU2391337C2 |
| USE OF RKS INHIBITORS IN DIABETES RELATED COMPLICATIONS | 2007 |
|
RU2447892C2 |
| NOVEL SPIROPENTACYCLIC COMPOUNDS | 2005 |
|
RU2360909C2 |
| APPLICATION OF DPP-IV INHIBITOR FOR REDUCTION OF GLYCEMIA ACUTE EXACERBATION | 2006 |
|
RU2440143C2 |
| NOVEL FATTY ACID ANALOGS FOR TREATMENT OF DIABETES | 1999 |
|
RU2221558C2 |
| PHARMACEUTICAL COMPOSITION INCLUDING SELECTIVE AGONIST OF IMIDAZOLINE RECEPTOR I1 AND BLOCKER OF ANGIOTENSIN II RECEPTOR | 2004 |
|
RU2362561C2 |
| USING CANNABINOIDS COMBINED WITH ANTIPSYCHOTIC DRUG PREPARATION | 2008 |
|
RU2503448C2 |
| METHOD OF TREATING PATHOLOGICAL SYNDROME AND DRUG OF CENTRAL AND PERIPHERAL ACTION FOR TREATING PATHOLOGICAL SYNDROME | 2011 |
|
RU2610438C2 |
| THERAPEUTIC TREATMENT OF METABOLIC SYNDROME, TYPE 2 DIABETES, OBESITY OR POTENTIAL DIABETES | 2008 |
|
RU2467743C2 |
| ACYLATED GLUCAGON ANALOGUE, USE THEREOF AND METHODS OF PRODUCING | 2016 |
|
RU2735762C2 |
